Michael Ryskin

Ekaterina Knyazkova

Navann Ty Dietschi

Navann Ty

Balaji Prasad

Linda Bolduc

- Phibro Animal Health Corporation reported strong financial results for the fourth quarter ended June 30, 2025, with **net sales increasing 39% to $378.7 million** and **adjusted diluted EPS rising 39% to $0.57**.  **[1069899_0001558370-25-011778_pahc-20250827xex99d1.htm:0]** 
- For the full fiscal year ended June 30, 2025, **net sales grew 27% to $1,296.2 million** and **adjusted EBITDA increased 65% to $183.7 million**.  **[1069899_0001558370-25-011778_pahc-20250827xex99d1.htm:0]** 
- The company attributed the growth to sustained demand across MFAs, nutritional specialties, and vaccines, with the **Zoetis MFA portfolio contributing to a 54% year-over-year increase in MFA and Other product sales**.  **[1069899_0001558370-25-011778_pahc-20250827xex99d1.htm:0]** 
- Phibro provided financial guidance for the fiscal year ending June 30, 2026, projecting **net sales of $1.43 billion to $1.48 billion** and **adjusted EBITDA of $225 million to $235 million**.  **[1069899_0001558370-25-011778_pahc-20250827xex99d1.htm:0]** **[1069899_0001558370-25-011778_pahc-20250827xex99d1.htm:6]**

PHIBRO ANIMAL HEALTH (PAHC)